Research Summary

Dr. Brian Schulte is a hematologist-oncologist who cares for patients with sarcomas, rare cancers that develop in connective tissues (such as bone, muscle or cartilage) and can affect people of all ages. Working as part of a multidisciplinary team, he strives to ensure patients receive the best possible comprehensive care. In research, Dr. Schulte studies novel medications, alone and in combination, to treat sarcoma.
After earning a bachelor's degree in engineering at Duke University, Dr. Schulte earned his medical degree at the Medical College of Wisconsin and completed a residency in internal medicine at the University of Colorado Anschutz Medical Campus. He completed a fellowship in hematology-oncology at Northwestern University Feinberg School of Medicine, where he served as chief fellow.


10/2021 - Diversity, Equity, and Inclusion Champion Training, University of California
06/2021 - Hematology/Oncology, Northwestern University
06/2018 - Internal Medicine, University of Colorado
MD, 05/2015 - , Medical College of Wisconsin
BSE, 05/2009 - Biomedical Engineering, Duke University

Honors & Awards

  • Chief Fellow Hematology/Oncology, Northwestern University, 2019-2020
  • Alpha Omega Alpha, 2014

Selected Publications

  1. Schulte B. Capacity of ChatGPT to Identify Guideline-Based Treatments for Advanced Solid Tumors. Cureus. 2023 Apr; 15(4):e37938.  View on PubMed
  2. Fuchs JW, Schulte BC, Fuchs JR, Agulnik M. Targeted therapies for the treatment of soft tissue sarcoma. Front Oncol. 2023; 13:1122508.  View on PubMed
  3. Fuchs JR, Schulte BC, Fuchs JW, Agulnik M. Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma. Front Oncol. 2023; 13:1123464.  View on PubMed
  4. Zhang S, Black RG, Kohli K, Hayes BJ, Miller C, Koehne A, Schroeder BA, Abrams K, Schulte BC, Alexiev BA, Heimberger AB, Zhang A, Jing W, Ng JCK, Shinglot H, Seguin B, Salter AI, Riddell SR, Jensen MC, Gottschalk S, Moore PF, Torok-Storb B, Pollack SM. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. Mol Cancer Ther. 2022 06 01; 21(6):999-1009.  View on PubMed
  5. Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, Jones RL, Cranmer LD, Pollack SM. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. J Immunother Cancer. 2021 08; 9(8).  View on PubMed
  6. Agulnik M, Schulte B, Robinson S, Hirbe AC, Kozak K, Chawla SP, Attia S, Rademaker A, Zhang H, Abbinanti S, Cehic R, Monga V, Milhem M, Okuno S, Van Tine BA. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021 09; 154:201-208.  View on PubMed
  7. Principe DR, Schulte BC, Kamath SD, Munshi HG. Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors. BMJ Case Rep. 2021 Jun 22; 14(6).  View on PubMed
  8. Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer. 2021 08; 125(4):528-533.  View on PubMed
  9. Lambden JP, Kelsten MF, Schulte BC, Abbinanti S, Hayes JP, Villaflor V, Agulnik M. Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report. Oncologist. 2021 07; 26(7):549-553.  View on PubMed
  10. Schulte B, Morgans AK, Shore ND, Pezaro C. Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-10.  View on PubMed
  11. Zhang W, Jordan KR, Schulte B, Purev E. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Des Devel Ther. 2018; 12:3343-3356.  View on PubMed
  12. Schulte BC, Wu W, Rosen T. Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application. J Drugs Dermatol. 2015 Sep; 14(9):964-8.  View on PubMed
  13. Wu X, Schulte BC, Zhou Y, Haribhai D, Mackinnon AC, Plaza JA, Williams CB, Hwang ST. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014 Nov; 134(11):2814-2822.  View on PubMed

Go to UCSF Profiles, powered by CTSI